KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Operating Margin (2017 - 2026)

Aquestive Therapeutics has reported Operating Margin over the past 9 years, most recently at 221.58% for Q4 2025.

  • For Q4 2025, Operating Margin fell 10716.0% year-over-year to 221.58%; the TTM value through Dec 2025 reached 159.5%, down 10605.0%, while the annual FY2025 figure was 159.5%, 10605.0% down from the prior year.
  • Operating Margin for Q4 2025 was 221.58% at Aquestive Therapeutics, down from 89.63% in the prior quarter.
  • Over five years, Operating Margin peaked at 0.27% in Q2 2024 and troughed at 325.85% in Q2 2021.
  • A 5-year average of 101.59% and a median of 84.5% in 2022 define the central range for Operating Margin.
  • On a YoY basis, Operating Margin climbed as much as 28456bps in 2021 and fell as far as -40485bps in 2021.
  • Year by year, Operating Margin stood at 105.33% in 2021, then rose by 5bps to 100.29% in 2022, then skyrocketed by 70bps to 29.62% in 2023, then tumbled by -286bps to 114.43% in 2024, then tumbled by -94bps to 221.58% in 2025.
  • Business Quant data shows Operating Margin for AQST at 221.58% in Q4 2025, 89.63% in Q3 2025, and 113.65% in Q2 2025.